The Company is pleased to announce the achievement of certain milestones in their initial phase of commercialization for the Rapid Viral Assay (RVA).
1. Successful Detection of irradiated (inactive) COVID-19 virus and its associated Spike Protein.
2. Non-Detection of Heat-Killed COVID-19 virus.
3. Limits of Detection (LOD) in the range of 10 Nanograms per milliliter of sample in 20 minutes.
What do these mean?
The RVA, unlike PCR technology, detects the whole virus and will not react to the presence of dead or nonpathogenic viral particles. This essentially eliminates false positives. (More routine testing such as PCR is plagued by false positives, due to the inability of PCR to distinguish between fragments of inactive virus and intact virus.)
The low threshhold for detection (meaning the RVA is more sensitive than other common tests), reduces the potential for false negative readings.
The RVA, as a detector of whole virions, should be able to detect pathogenic mutations, or variants, for the targeted virus. This means that as the virus continues to mutate and evolve, the RVA does not have to be modified in order to continue to maintain its accuracy.
The RVA development research is currently focused upon adaptation to a cartridge format that will provide ease of use and affordability.
The RVA is the only technology we know that tests for the whole virus.
The RVA is the only technology we know that is capable of determining if an individual is contagious.
This update or press release contains statements which may constitute “forward- looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.